Skip to main content
logo
TaiMed Biologics Inc. (TPEX:4147)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
62.20
-0.90 (-1.43%)
Aug 19, 2026, 9:48 AM CST

TaiMed Biologics Financials Overview

Millions TWD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
619.49611.35610.16491.78563.01413.44
Revenue Growth
3.58%0.19%24.07%-12.65%36.18%-42.77%
Gross Profit
266.85259.45211.23225.23215.7183.96
Operating Income
-187.53-194.65-252.27-166.23-191.86-486.37
Net Income
-138.9-167.78-201.83-194.81-269.29-470.93
Earnings Per Share
-0.51-0.61-0.75-0.77-1.07-1.87
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
1,6071,7681,652646.5642.79958.3
Total Debt
450493.12522.63750.86766.14567.32
Net Cash (Debt)
1,1571,2751,130-104.35-123.35390.98
Net Cash Growth
1.61%12.86%----38.12%
Net Cash Per Share
4.294.674.21-0.41-0.491.55

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
155.12191.14-379.55-25.6-605.21-211.28
Capital Expenditures
-47.11-22.67-8.06-6.15-3.56-9.69
Free Cash Flow
108.01168.48-387.61-31.75-608.77-220.96
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
43.08%42.44%34.62%45.80%38.31%20.31%
Operating Margin
-30.27%-31.84%-41.34%-33.80%-34.08%-117.64%
Pretax Margin
-22.42%-27.44%-33.08%-39.61%-47.83%-113.91%
Profit Margin
-22.42%-27.44%-33.08%-39.61%-47.83%-113.90%
FCF Margin
17.44%27.56%-63.52%-6.46%-108.13%-53.44%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Forward PE
-46.4846.48282.7641.73182.22
P/FCF Ratio
159.6199.24----
PS Ratio
27.8327.3538.4942.1931.6943.09